JD Capital-invested Panlong Pharmaceutical Approved for IPO
Panlong Pharmaceutical currently has the approval certificates for production of 73 drugs under 9 dosage forms. It also produces three varieties of health care products. Its product line is multi-tier, diverse in dosage form, and is sold in 28 Chinese provinces, autonomous regions and municipalities. The company has established long-term stable business relations with more than 300 domestic pharmaceutical companies, through which its products are sold in over 2,000 hospitals and large drugstores nationwide.
The fund ran by JD Capital bought shares of Panlong Pharmaceutical in June, 2012 and holds 30% of its shares prior to IPO.
So far in 2017, 10 enterprises invested by JD Capital have gone or will go public on the A-stock market. They are Panlong Pharmaceutical, Jiudian Pharmaceutical, Chanhen Chemical, Cisen Pharmaceutical, Jinneng Science and Technology, KE Electric, Chengyi Pharmaceutical, Juewei Food, Doctorglasses, and Huida Sanitary Ware.